Table 1.
Demographic and clinicopathologic characteristics of 80 anaplastic lymphoma kinase (ALK)‐positive patients who received crizotinib or chemotherapy as first‐line treatment
| Characteristic | Total N = 80n (%) | Crizotinib N = 30n (%) | Chemotherapy N = 50n (%) | P‐Value |
|---|---|---|---|---|
| Age, years | ||||
| Mean | 54 | 58 | 52 | |
| Range | 26–83 | 37–83 | 26–72 | |
| Age distribution | ||||
| <60 years | 49 (61) | 17 (57) | 32 (64) | 0.636 |
| ≥60 years | 31 (39) | 13 (43) | 18 (36) | |
| Gender | ||||
| Male | 38 (48) | 15 (50) | 23 (46) | 0.819 |
| Female | 42 (52) | 15 (50) | 27 (54) | |
| ECOG PS | ||||
| 0 | 22 (28) | 8 (27) | 14 (28) | 1.000 |
| 1 | 55 (69) | 21 (70) | 34 (68) | |
| 2 | 3 (3) | 1 (3) | 2 (4) | |
| Radical surgery history | ||||
| Yes | 17 (21) | 7 (23) | 10 (20) | 0.781 |
| No | 63 (79) | 23 (77) | 40 (80) | |
| Smoking history | ||||
| Never | 59 (74) | 23 (77) | 36 (72) | 0.625 |
| ≤10 pack‐year | 10 (13) | 1 (3) | 5 (10) | |
| >10 pack‐year | 11 (13) | 6 (20) | 9 (18) | |
| Clinical stage | ||||
| IIIB | 6 (8) | 1 (3) | 5 (10) | 0.402 |
| IV | 74 (92) | 29 (97) | 45 (90) | |
ECOG PS, Eastern cooperative oncology group performance status.